Trial Profile
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Doxercalciferol (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 10 Oct 2016 Status changed from active, no longer recruiting to completed.
- 04 Oct 2005 New trial record.